Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
H-Biota is a South Korean biotechnology company specializing in the development of microbiome-based therapeutics and diagnostic tools. Founded by Professor Bong-su Kim of Inha University, the company leverages its proprietary platform to analyze the human microbiome and identify beneficial microbial strains for treating various conditions, including atopic dermatitis and oral diseases. H-Biota's pipeline includes live biotherapeutic products (LBPs) aimed at restoring microbial balance to address systemic and localized inflammatory disorders. The company also develops microbiome-related health functional foods and diagnostic services to provide a comprehensive approach to microbiome health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on H-biota.